VOL 36 Supplement No. 3

Burgeoning advances in the neurosciences have been increasingly applied to psychopharmacology, and the reports that follow provide a glimpse into this process. Several of the leading investigators on the cutting edge of this rapidly evolving...

Major depressive disorder is currently the fourth largest contributor to the worldwide burden of disease. Direct and indirect costs associated with depression place a significant burden on the healthcare system and society. Despite the development...

Major depressive disorder (MDD) is a common and costly illness. Recent research suggests that MDD is a lifelong condition for many patients. This has stimulated researchers to identify risk factors associated with an increased frequency...

Approximately 30% of patients with major depression respond poorly to treatment with any given antidepressant regimen, and as many as 60% to 75% experience residual or recurrent symptoms. Strategies for improving response include extending the...

The functional anatomy of anxiety focuses on a central fear response system, with the amygdala serving as a pivotal hub. Critical to understanding the different forms of human anxiety is the relationship of the amygdala...

Anxiety disorders are highly prevalent and associated with significant symptomatic distress, increased morbidity, and increased mortality. Although efficacious pharmacologic and psychosocial therapies for anxiety disorders are available, many patients who improve with treatment remain at...

Epidemiological studies have shown that the prevalence of depression is about twice as high in women as in men. Both neurobiological and psychosocial factors may contribute to this difference. Gender differences in depression have also...

Depression, a heterogeneous disease often accompanied by significant medical and psychiatric comorbidity, is common among the elderly. Clinicians caring for depressed elders should look for comorbidities, as they may affect management of the patient. For...